An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species
Year: 2024
Type: article
Abstract: Recombinant adeno-associated viruses (rAAVs) have emerged as promising gene therapy vectors due to their proven efficacy and safety in clinical applications. In non-human primates (NHPs), rAAVs are administered via suprachoroidal injection at a higher dose. However, high doses of rAAVs tend to increase additional safety risks. Here, we present a novel AAV capsid (AAVv128), which exhibits significantly enhanced transduction efficiency for photoreceptors and retinal pigment epithelial (RPE) cells, along with a broader distribution across the layers of retinal tissues in different animal models (mice, rabbits, and NHPs) following intraocular injection. Notably, the suprachoroidal delivery of AAVv128-anti-VEGF vector completely suppresses the Grade IV lesions in a laser-induced choroidal neovascularization (CNV) NHP model for neovascular age-related macular degeneration (nAMD). Furthermore, cryo-EM analysis at 2.1 Å resolution reveals that the critical residues of AAVv128 exhibit a more robust advantage in AAV binding, the nuclear uptake and endosome escaping. Collectively, our findings highlight the potential of AAVv128 as a next generation ocular gene therapy vector, particularly using the suprachoroidal delivery route.
Source: Nature Communications
Institutions: Sichuan University, Guangzhou Laboratory
Language: English
Subfield: Genetics
Domain: Life Sciences
Keywords: adeno-associated virus, ocular gene delivery, suprachoroidal injection, retinal transduction, photoreceptors, retinal pigment epithelium, choroidal neovascularization, neovascular age-related macular degeneration, anti-VEGF therapy, non-human primates, cryo-EM structure, endosomal escape, nuclear uptake, retinal gene therapy
Open Access status: gold
Estimated APC paid: $6,790
Awards: G2085516865, G2422626743
OpenAlex ID: W4396673495
